MA40281A - Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t - Google Patents

Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t

Info

Publication number
MA40281A
MA40281A MA040281A MA40281A MA40281A MA 40281 A MA40281 A MA 40281A MA 040281 A MA040281 A MA 040281A MA 40281 A MA40281 A MA 40281A MA 40281 A MA40281 A MA 40281A
Authority
MA
Morocco
Prior art keywords
sup
calcium channel
type calcium
blocking agents
channel blocking
Prior art date
Application number
MA040281A
Other languages
English (en)
Other versions
MA40281B1 (fr
Inventor
Olivier Bezencon
John Gatfield
Bibia Heidmann
Romain Siegrist
Simon Stamm
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA40281A publication Critical patent/MA40281A/fr
Publication of MA40281B1 publication Critical patent/MA40281B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

L'invention concerne des composés de formule (i) formule (i) dans laquelle x, y, r<sup>1</sup>, r<sup>2</sup>, (r<sup>4</sup>)<sub>n</sub>, et (r<sup>5</sup>)<sub>m</sub> sont tels que définis dans la description, et des sels pharmaceutiquement acceptables de ces composés. Ces composés sont utiles en tant que bloqueurs des canaux calciques de type t
MA40281A 2014-06-03 2015-06-02 Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t MA40281B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2014061901 2014-06-03
PCT/IB2015/054164 WO2015186056A1 (fr) 2014-06-03 2015-06-02 Composés de pyrazole et leur utilisation en tant que bloqueurs des canaux calciques de type t
EP15728640.2A EP3152199B1 (fr) 2014-06-03 2015-06-02 Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t

Publications (2)

Publication Number Publication Date
MA40281A true MA40281A (fr) 2015-12-10
MA40281B1 MA40281B1 (fr) 2018-11-30

Family

ID=53385705

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40281A MA40281B1 (fr) 2014-06-03 2015-06-02 Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t

Country Status (32)

Country Link
US (2) US9932314B2 (fr)
EP (1) EP3152199B1 (fr)
JP (1) JP6195684B2 (fr)
KR (1) KR101906031B1 (fr)
CN (1) CN106414429B (fr)
AR (1) AR100712A1 (fr)
AU (1) AU2015270118C1 (fr)
CA (1) CA2947002C (fr)
CL (1) CL2016003092A1 (fr)
CY (1) CY1120864T1 (fr)
DK (1) DK3152199T3 (fr)
EA (1) EA031104B1 (fr)
ES (1) ES2696351T3 (fr)
HR (1) HRP20181670T1 (fr)
HU (1) HUE040489T2 (fr)
IL (1) IL249275B (fr)
LT (1) LT3152199T (fr)
MA (1) MA40281B1 (fr)
MX (1) MX2016015923A (fr)
NZ (1) NZ727818A (fr)
PE (1) PE20170129A1 (fr)
PH (1) PH12016502230B1 (fr)
PL (1) PL3152199T3 (fr)
PT (1) PT3152199T (fr)
RS (1) RS57943B1 (fr)
SG (1) SG11201609974PA (fr)
SI (1) SI3152199T1 (fr)
TN (1) TN2016000542A1 (fr)
TR (1) TR201816624T4 (fr)
TW (2) TWI690513B (fr)
WO (1) WO2015186056A1 (fr)
ZA (1) ZA201608821B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20170129A1 (es) 2014-06-03 2017-03-30 Actelion Pharmaceuticals Ltd Compuestos de pirazol y su uso como bloqueadores de los canales de calcio tipo t
MX367519B (es) 2014-09-15 2019-08-26 Idorsia Pharmaceuticals Ltd Compuestos triazolicos como bloqueadores de canales de calcio tipo t.
RU2018128334A (ru) * 2016-02-09 2020-03-10 Инвентисбио Инк. Ингибиторы индоламин-2,3-диоксигеназы (ido)
US11046683B2 (en) 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
JP6931701B2 (ja) * 2016-12-16 2021-09-08 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｔ型カルシウムチャンネルブロッカーを含有する薬学的合剤
US20210128537A1 (en) * 2016-12-21 2021-05-06 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
CN110234622B (zh) * 2017-02-06 2023-07-04 爱杜西亚药品有限公司 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法
AU2018296423B2 (en) 2017-07-05 2022-07-28 Idorsia Pharmaceuticals Ltd Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
JP7462569B2 (ja) * 2017-12-12 2024-04-05 クィーンズ ユニバーシティー アット キングストン Ｃｙｐ２６酵素を阻害するための化合物および方法
MX2022000492A (es) 2019-07-11 2022-07-04 Praxis Prec Medicines Inc Formulaciones de moduladores de canal de calcio tipo t y metodos de uso de estos.
CA3146157A1 (fr) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Composes de sulfone et leurs compositions pharmaceutiques, et leurs applications therapeutiques pour le traitement de maladies neurodegeneratives
JP2023507430A (ja) 2019-12-20 2023-02-22 イドルシア ファーマスーティカルズ リミテッド Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセトアミドを含む薬学的組成物
BR112023026062A2 (pt) * 2021-07-02 2024-03-05 Lg Chemical Ltd Método para preparar um composto
WO2023240205A1 (fr) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Composés deutérés

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700068A (es) 1994-06-24 1997-12-31 Euro Celtique Sa Compuestos y metodo para inhibir a la fosfodiesterasa iv.
HUP0000735A3 (en) 1996-12-23 2002-03-28 Bristol Myers Squibb Pharma Co Nitrogen containing heteroaromatics as factor xa inhibitors
WO2002000651A2 (fr) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
WO2002053160A1 (fr) 2000-12-29 2002-07-11 Alteon, Inc. Methode de traitement du glaucome ivb
AU2002232919A1 (en) 2000-12-29 2002-07-16 Alteon, Inc. Method for treating fibrotic diseases or other indications
CA2465207C (fr) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides et -sulfonamides
ES2292854T3 (es) 2001-12-18 2008-03-16 MERCK &amp; CO., INC. Moduladores triazol sustituidos con heteroarilo del receptor-5 metabotropico de glumatamato.
WO2003051833A2 (fr) 2001-12-18 2003-06-26 Merck & Co., Inc. Modulateurs pyrazole a substitution heteroaryle du recepteur 5 metabotropique de glutamate
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
WO2004089303A2 (fr) 2003-04-03 2004-10-21 Merck & Co., Inc. Modulateurs au pyrazole a substitution diaryle du recepteur-5 de glutamate metabotropique
CA2521396A1 (fr) 2003-04-04 2004-10-21 Merck & Co., Inc. Modulateurs au triazole a substitution diaryle du recepteur-5 de glutamate metabotropique
JP2006525355A (ja) * 2003-05-01 2006-11-09 アボット・ラボラトリーズ ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
BRPI0514425A (pt) 2004-08-18 2008-06-10 Pfizer inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
US20100137378A1 (en) 2004-12-23 2010-06-03 Glaxo Group Limited Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
FR2889234B1 (fr) * 2005-07-27 2007-11-23 Andre Prieur Arret de porte a positions de maintien indeterminees
KR100654328B1 (ko) * 2005-08-26 2006-12-08 한국과학기술연구원 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법
CA2634147A1 (fr) 2005-12-22 2007-06-28 Icagen, Inc. Antagonistes des canaux calciques
CN101466676B (zh) * 2006-04-12 2012-07-18 默沙东公司 吡啶基酰胺类t-型钙通道拮抗剂
AU2007278261A1 (en) * 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008085888A1 (fr) 2007-01-05 2008-07-17 Arena Pharmaceuticals, Inc. Récepteur couplé aux protéines g et modulateur dudit récepteur pour le traitement de troubles neurologiques liés au gaba et notamment de troubles liés au sommeil
CA2690141A1 (fr) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Inhibiteurs des janus kinases
EP2195304B1 (fr) * 2007-10-08 2014-01-08 Advinus Therapeutics Private Limited Dérivés acétamide comme activateurs de la glucokinase, leur procédé et applications médicinales
US20100216816A1 (en) 2007-10-24 2010-08-26 Barrow James C Pyrazinyl amide-t type calcium channel antagonists
EP2212291B1 (fr) 2007-10-24 2014-06-04 Merck Sharp & Dohme Corp. Antagonistes de canaux calciques de type t à base de phényle amide hétérocyclique
WO2009054983A1 (fr) 2007-10-24 2009-04-30 Merck & Co., Inc. Antagonistes des canaux calciques de type t à base d'amide hétérocyclique
WO2009118596A2 (fr) 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Dérivés de phtalimide en tant que modulateurs de trpa1
US20100305120A1 (en) 2008-04-04 2010-12-02 Biomarin Iga Limited Compounds for treating muscular dystrophy
WO2010004390A1 (fr) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Dérivés de quinazoline dione en tant que modulateurs de trpa1
KR101052065B1 (ko) * 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
WO2010073011A2 (fr) 2008-12-23 2010-07-01 Betagenon Ab Composés utiles comme médicaments
JP2012516885A (ja) 2009-02-04 2012-07-26 ファイザー・インク ４−アミノ−７，８−ジヒドロピリド［４，３−ｄ］ピリミジン−５（６Ｈ）−オン誘導体
TW201103892A (en) 2009-04-24 2011-02-01 Glaxo Group Ltd Compounds
EP2421834A1 (fr) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole et triazole carboxamides en tant qu'inhibiteurs du canal crac
EP2438064A1 (fr) 2009-06-04 2012-04-11 Novartis AG Dérivés de la 1h-imidazo[4,5-c]quinolinone
WO2011022315A1 (fr) 2009-08-19 2011-02-24 Merck Sharp & Dohme Corp. Antagonistes de canal calcium de type t de pyrazinylphénylamide
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
EP2493297B1 (fr) 2009-10-30 2016-08-17 Merck Sharp & Dohme Corp. Antagonistes des canaux calciques de type t amides hétérocycliques
US20120264735A1 (en) 2009-12-21 2012-10-18 Jonathan Young Tyrosine kinase inhibitors
WO2011093352A1 (fr) 2010-01-27 2011-08-04 武田薬品工業株式会社 Dérivé de thiazole
EP2402327B1 (fr) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Composés d'acétamide en tant qu'activateurs de la glucokinase, leur procédé et applications médicales
JP5862669B2 (ja) 2010-08-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
UA107423C2 (en) 2011-03-07 2014-12-25 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9868748B2 (en) * 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
EP2848615A1 (fr) * 2013-07-03 2015-03-18 Almirall, S.A. Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC
KR101685993B1 (ko) 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
PE20170129A1 (es) 2014-06-03 2017-03-30 Actelion Pharmaceuticals Ltd Compuestos de pirazol y su uso como bloqueadores de los canales de calcio tipo t
MX367519B (es) 2014-09-15 2019-08-26 Idorsia Pharmaceuticals Ltd Compuestos triazolicos como bloqueadores de canales de calcio tipo t.
JP6728198B2 (ja) 2015-01-30 2020-07-22 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 置換トリアゾールおよびそれに関する方法
DK3778595T3 (da) * 2015-02-27 2021-10-18 Calcimedica Inc Pancreatitisbehandling

Also Published As

Publication number Publication date
SG11201609974PA (en) 2016-12-29
RS57943B1 (sr) 2019-01-31
TWI675827B (zh) 2019-11-01
MA40281B1 (fr) 2018-11-30
HUE040489T2 (hu) 2019-03-28
LT3152199T (lt) 2018-11-12
AU2015270118B2 (en) 2019-09-12
EP3152199B1 (fr) 2018-08-15
US20170096399A1 (en) 2017-04-06
AU2015270118A1 (en) 2017-01-12
CN106414429A (zh) 2017-02-15
EA201692521A1 (ru) 2017-05-31
KR101906031B1 (ko) 2018-10-08
SI3152199T1 (sl) 2018-12-31
TW201625551A (zh) 2016-07-16
JP2017516830A (ja) 2017-06-22
HRP20181670T1 (hr) 2018-12-14
CA2947002A1 (fr) 2015-12-10
CL2016003092A1 (es) 2017-05-12
PT3152199T (pt) 2018-11-26
KR20170012432A (ko) 2017-02-02
EA031104B1 (ru) 2018-11-30
TR201816624T4 (tr) 2018-11-21
WO2015186056A1 (fr) 2015-12-10
TW201930270A (zh) 2019-08-01
PH12016502230A1 (en) 2017-01-09
ES2696351T3 (es) 2019-01-15
EP3152199A1 (fr) 2017-04-12
NZ727818A (en) 2020-06-26
IL249275B (en) 2020-01-30
BR112016028315A8 (pt) 2017-12-26
AR100712A1 (es) 2016-10-26
CY1120864T1 (el) 2019-12-11
MX2016015923A (es) 2017-02-27
US9932314B2 (en) 2018-04-03
PE20170129A1 (es) 2017-03-30
ZA201608821B (en) 2019-05-29
BR112016028315A2 (pt) 2017-08-22
PL3152199T3 (pl) 2019-01-31
PH12016502230B1 (en) 2017-01-09
TN2016000542A1 (en) 2018-04-04
CN106414429B (zh) 2020-01-03
US10065929B2 (en) 2018-09-04
CA2947002C (fr) 2023-01-03
AU2015270118C1 (en) 2019-11-28
TWI690513B (zh) 2020-04-11
JP6195684B2 (ja) 2017-09-13
DK3152199T3 (en) 2018-11-26
IL249275A0 (en) 2017-02-28
US20180105496A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
MA40281A (fr) Composés de pyrazole et leur utilisation en tant qu&#39; agents de blocage des canaux calciques de type t
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018500065A1 (en) Oxysterols and methods of use thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
UY35288A (es) Piridonamidas como moduladores de canales de sodio
MA39995B1 (fr) Composés destinés à traiter l&#39;amyotrophie spinale
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
EA201791304A1 (ru) Производные изохинолина для лечения вич
MA39956A (fr) Analogues du benzomorphane et leur utilisation
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d&#39;orexine
MA40302B1 (fr) Dérivés de carbazole
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
MX2018002006A (es) Benzamidas apareadas novedosas.
EA201790613A1 (ru) Триазольные соединения в качестве блокаторов кальциевых каналов т-типа
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2017001720A1 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos.
CL2015002188A1 (es) Agentes analgésicos oculares tópicos